OCGN logo

OCGN
Ocugen Inc

154,208
Mkt Cap
$470.55M
Volume
4.79M
52W High
$2.73
52W Low
$0.73
PE Ratio
-6.00
OCGN Fundamentals
Price
$1.39
Prev Close
$1.46
Open
$1.44
50D MA
$1.82
Beta
1.58
Avg. Volume
5.78M
EPS (Annual)
-$0.226
P/B
81.00
Rev/Employee
$38,043.10
$419.80
Loading...
Loading...
News
all
press releases
Ocugen (OCGN) Upgraded to Buy: Here's Why
Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·8d ago
News Placeholder
More News
News Placeholder
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.
Zacks·10d ago
News Placeholder
Ocugen, Inc. (NASDAQ:OCGN) Given Average Recommendation of "Moderate Buy" by Brokerages
Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) has been assigned an average rating of 'Moderate Buy' from the five research firms that are presently covering the company, MarketBeat Ratings reports...
MarketBeat·11d ago
News Placeholder
Ocugen Q1 Earnings Call Highlights
Ocugen (NASDAQ:OCGN) used its first-quarter 2026 earnings call to highlight progress across its retinal gene therapy pipeline and to outline a strengthened balance sheet following a newly announced...
MarketBeat·11d ago
News Placeholder
Ocugen (NASDAQ:OCGN) Issues Earnings Results, Misses Expectations By $0.01 EPS
Ocugen (NASDAQ:OCGN - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18...
MarketBeat·11d ago
News Placeholder
Ocugen (NASDAQ:OCGN) Shares Gap Down on Disappointing Earnings
Ocugen (NASDAQ:OCGN) Shares Gap Down Following Weak Earnings...
MarketBeat·11d ago
News Placeholder
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Ocugen (OCGN) Expected to Announce Earnings on Friday
Ocugen (NASDAQ:OCGN) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-8-ocugen-inc-stock...
MarketBeat·16d ago
News Placeholder
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
Zacks·24d ago
News Placeholder
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.
Zacks·24d ago
<
1
2
...
>

Latest OCGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.